{"classes":[{"categories":[{"measurements":[{"comment":"The confidence interval cannot be calculated for a single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"DOR was defined as the time from the first CR or PR until disease progression by investigator assessment per RECIST v1.1 or death from any cause, whichever occurred earlier. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.","id":"OG000","title":"INCB099280 400 mg BID Plus Axitinib 5 mg BID"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. Only participants with a CR or PR were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 335 days","title":"Part 1: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}